<DOC>
	<DOCNO>NCT01972672</DOCNO>
	<brief_summary>The primary objective study assess time progression ( TTP ) patient advance HCC treat Icaritin .</brief_summary>
	<brief_title>The Phase II Study Icaritin Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Icaritin newly discover small molecular compound high selective ERa36 modulators , preclinical PK &amp; PD toxicity study show inhibit growth HCC cancer cell vitro vivo , combine clinical data perhaps promise new drug treat hepatocellular carcinoma ( HCC ) target nongenomic pathway . Shenogen decide investigate efficacy safety Icaritin explore potential gene target treat HCC . The result phase I study show Icaritin good safety tolerance . The biological availability Icaritin meal high half-life relatively short . The phase Ib study enrol 28 subject . Among 18 HCC subject , 12 subject receive treatment oral administration group 600 mg , twice per day , meal 30 minute , 6 subject receive treatment oral administration group 800 mg , twice per day , meal 30 minute . The result show 600mg group 12 HCC patient whose therapeutic efficacy evaluable , one case PR ( 10 % ) , 5 case SD ( 50 % ) 4 case PD ( 40 % ) observed.Safety data show totally 24 AEs probably relate investigational drug . Among , 19 AEs grade I , 5 AEs grade II , grade III AE .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients may enter study meet follow criterion : 1 . The age 18 75 . 2 . Patients HCC histologically cytologically confirm . At least one lesion , previously treat ( accurately measure baseline ≥ 10 mm long diameter compute tomography ( CT ) per RECIST 1.1 ) 3 . Patients accept willing surgery interventional therapy via hepatic artery , surgery Interventional therapy via hepatic artery 4 week disease progression , tolerate Sorafenib Oxaliplatin doublet chemotherapy use refuse use 4 . ChildPugh status A B ( ≤7 ) ( Either albumin haemachrome &gt; 2 ) 5 . ECOG PS : 0 1 . 6 . Patients life expectancy least 12 week . 7 . Patients receive chemotherapy target therapy . If patient receive radiation therapy surgery , treatment least 4 week prior enrollment AE wound treatment recover . If patient receive adjuvant chemotherapy , treatment least 6 month prior enrollment . 8 . Meet follow laboratory parameter : Haematology ( blood transfusion Blood product Hematopoietic growth factor within 14 day ) 1 . Hemoglobin ≥ 90 g/dL 2 . Neutrophil cell count≥1.5 × 10^9/L 3 . Platelet count ≥ 80 × 10^9/L Clinical chemistry , 1 . Albumin ≥ 29 g/dL ( albumin transfusion blood product within 14 day ) 2 . ALT AST &lt; 5 × ULN 3 . Total bilirubin ≤ 1.5 × ULN 4 . Serum creatinine ≤ 1.5 × ULN 9 . If HBVDNA≥10^4 , antivirus therapy use HBVDNA &lt; 10^4 10 . Patients willing participate study good compliance must give write informed consent prior study specific screen 11 . Patients participate study 4 week prior enrollment adverse event occur recover . Patients meet criterion include study : 1 . Previously know intrahepatic cholangiocarcinoma , mixed cell carcinoma fibrolamellar carcinoma ; previous concurrent malignant tumor ( heal skin basal cell carcinoma carcinoma situ uterine cervix include ) ; 2 . Women pregnancy lactation ; 3 . Patients hypertension blood pressure well control treatment antihypertensive drug ( systolic pressure &gt; 150mmHg , diastolic pressure &gt; 100mmHg ) ; patient grade II high myocardial ischemia myocardial infarction poorly control arrhythmia ( include QTC interval≥ 450ms ) grade IIIIV cardiac insufficiency accord NYHA criterion ; Ultrasound Cardiogram heart : LVEF ( leave ventricular ejection fraction ) ＜50 % ; 4 . Patients incapable swallow , chronic diarrhea intestinal obstruction , significantly affect administration absorption study drug ; 5 . Patients potentially gastrointestinal hemorrhage ( local active ulcer focus , occult blood stool ++ even high ) , previous medical record alimentary tract hemorrhage within six month ; 6 . Patients central nervous system metastasis ; 7 . Patients coagulation disorder ( prothrombin time &gt; 16 , activate partial thromboplastin time &gt; 43s , thrombin time &gt; 21 , fibrinogen &lt; 2g/L ) , subject show hemorrhagic tendency accept thrombolytic anticoagulant therapy ; 8 . Patients psychiatric disorder previous medical history psychotropic drug abuse ; 9 . Patients seroperitoneum clinical symptom , requring remedial abdominal paracentesis drainage , ChildPugh score ≥2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>